Literature DB >> 18005145

Tissue plasminogen activator to prevent central venous access device infections: a systematic review of central venous access catheter thrombosis, infection and thromboprophylaxis.

M V Ragni1, J M Journeycake, D J Brambilla.   

Abstract

The recent unequivocal demonstration that prophylaxis, three to four weekly factor infusions, is effective in preventing joint disease in children with haemophilia, has provided impetus to initiate prophylaxis early in such children. Yet, nearly a quarter (22%) of the 83% who required central venous access devices for factor infusion developed central venous access catheter (CVAD)-related infection. This limitation of CVAD use prevents many families from initiating prophylaxis. The frequent occurrence of local thrombosis accompanying CVAD-related infection in surgical patients and autopsy cases, the thrombogenic plastic CVAD surfaces, and local clot formation at the insertion site, suggest the potential role of thrombolytic agents in preventing these infections. Yet, correlation between CVAD-related infection and local thrombosis in children with haemophilia are lacking, and thromboprophylaxis to prevent CVAD-related infection is controversial. Tissue plasminogen activator (t-PA), a recombinant serine protease glycoprotein that lyses plasmin-bound fibrin and is safe and effective in the treatment of occluded catheters, has not been evaluated in the prevention of these infections. We performed a literature review of CVAD-related infection, CVAD-related thrombosis, and thromboprophylaxis studies to evaluate the role of t-PA in the prevention of these infections in children with haemophilia. Metanalysis of published thromboprophylaxis trials demonstrate current prophylaxis regimens do not prevent CVAD infection, and further, that thrombosis and infection do not necessarily occur simultaneously. Pilot data demonstrate CVAD infection reduction in haemophilic children by monthly t-PA in 18 haemophilic children, suggesting the potential role of t-PA in CVAD infection prevention. Clinical trials to evaluate t-PA in CVAD infection prevention are justified.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18005145     DOI: 10.1111/j.1365-2516.2007.01599.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  5 in total

Review 1.  Management of occlusion and thrombosis associated with long-term indwelling central venous catheters.

Authors:  Jacquelyn L Baskin; Ching-Hon Pui; Ulrike Reiss; Judith A Wilimas; Monika L Metzger; Raul C Ribeiro; Scott C Howard
Journal:  Lancet       Date:  2009-07-11       Impact factor: 79.321

2.  Flushing ports of totally implantable venous access devices, and impact of the Huber point needle bevel orientation: experimental tests and numerical computation.

Authors:  Gérard Guiffant; Jean Jacques Durussel; Patrice Flaud; Jean Pierre Vigier; Jacques Merckx
Journal:  Med Devices (Auckl)       Date:  2012-04-16

3.  Impact of the shape of the implantable ports on their efficiency of flow (injection and flushing).

Authors:  Gérard Guiffant; Patrice Flaud; Jean Jacques Durussel; Jacques Merckx
Journal:  Med Devices (Auckl)       Date:  2014-09-17

4.  Mechanical characteristics of plastic base Ports and impact on flushing efficacy.

Authors:  Gérard Guiffant; Patrice Flaud; Laurent Royon; Espérie Burnet; Jacques Merckx
Journal:  Med Devices (Auckl)       Date:  2017-01-17

5.  Power port contrast medium flushing and trapping: impact of temperature, an in vitro experimental study.

Authors:  Gérard Guiffant; Jean Jacques Durussel; Patrice Flaud; Laurent Royon; Pierre Yves Marcy; Jacques Merckx
Journal:  Med Devices (Auckl)       Date:  2013-09-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.